Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.

PURPOSE Assess efficacy and toxicity of gefitinib, an epidermal growth factor receptor (EGFR) inhibitor, added to, and in maintenance after, concurrent chemoradiotherapy (CCRT) in locally advanced head and neck cancer (LA-HNC) and correlate outcomes with EGFR gene copy number alterations. PATIENTS AND METHODS Patients with stage III to IV LA-HNC received two cycles of carboplatin/paclitaxel induction chemotherapy (IC) followed by split-course CCRT with fluorouracil, hydroxyurea, twice daily radiotherapy (FHX), and gefitinib (250 mg daily) followed by continued gefitinib for 2 years total. The primary end point was complete response (CR) rate after CCRT. EGFR gene copy number was assessed by fluorescent in situ hybridization. RESULTS Sixty-nine patients (66 with stage IV disease, 37 with oropharynx primary tumors, and 67 with performance status 0 to 1) were enrolled with a median age of 55 years. Predominant grade 3 or 4 toxicities during IC and CCRT were neutropenia (n = 20) and in-field mucositis (n = 59) and dermatitis (n = 23), respectively. CR rate after CCRT was 90%. After median follow-up of 3.5 years, 4-year overall, progression-free, and disease-specific survival rates were 74%, 72%, and 89%, respectively. To date, one patient has developed a second primary tumor in the aerodigestive tract. In 31 patients with available tissue, high EGFR gene copy number was associated with worse overall survival (P = .02). CONCLUSION Gefitinib can be administered with FHX and as maintenance therapy for at least 2 years, demonstrating CR and survival rates that compare favorably with prior experience. High EGFR gene copy number may be associated with poor outcome in patients with LA-HNC treated with this regimen.

[1]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[2]  T. Gorlia,et al.  Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. , 2007, The New England journal of medicine.

[3]  Diane D. Liu,et al.  Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Day,et al.  Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .

[5]  T. Seiwert,et al.  State-of-the-art management of locally advanced head and neck cancer , 2005, British Journal of Cancer.

[6]  J. Bourhis,et al.  Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  G. Calais,et al.  Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. , 2009, Journal of the National Cancer Institute.

[8]  C. Bokemeyer,et al.  Biomarker potential of EGFR gene copy number by FISH in the phase III EXTREME study: Platinum-based CT plus cetuximab in first-line R/M SCCHN. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Christine H Chung,et al.  Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Vokes,et al.  Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.

[11]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[12]  J. Pignon,et al.  Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  Suzanne L Wolden,et al.  Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  E. Vokes,et al.  Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  J. Dancey,et al.  Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Jacques Ferlay,et al.  Estimates of the worldwide incidence of 25 major cancers in 1990 , 1999, International journal of cancer.

[17]  J. Dancey,et al.  Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study. , 2009, The Lancet. Oncology.

[18]  P. Harari,et al.  Radiation combined with EGFR signal inhibitors: head and neck cancer focus. , 2006, Seminars in radiation oncology.

[19]  V. Adamo,et al.  A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck , 2008, Anti-cancer drugs.

[20]  R. Tishler,et al.  Phase I dose-finding study of paclitaxel with panitumumab, carboplatin and intensity-modulated radiotherapy in patients with locally advanced squamous cell cancer of the head and neck. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  F. Hirsch,et al.  Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected]. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  F. Khuri,et al.  Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  J. Califano,et al.  Human Papillomavirus and Head and Neck Squamous Cell Carcinoma: Recent Evidence and Clinical Implications , 2009, Journal of dental research.

[24]  R. Day,et al.  Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. , 1998, Journal of the National Cancer Institute.

[25]  A. Markoe,et al.  Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. , 2007, The New England journal of medicine.

[26]  C. Gwede,et al.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. Crowley,et al.  Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  E. Vokes,et al.  Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Hanna Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group Study , 2007 .